Navion Capital II Terminates Non-Binding Maple Brain Letter of Intent
Navion Capital II Inc. has terminated its non-binding letter of intent with Maple Brain Healthcare Inc. and plans to request the resumption of trading in its common shares.
Navion Capital II Inc. (TSXV:NVN.P) has ended its previously announced non-binding letter of intent with Maple Brain Healthcare Inc. The agreement, dated October 24, 2025, concerned a proposed Qualifying Transaction under Policy 2.4 – Capital Pool Companies of the TSX Venture Exchange Corporate Finance Manual.
Navion said it will continue assessing assets and businesses as it seeks a Qualifying Transaction. The company also plans to monitor Maple Brain while that business continues its development.
In line with TSX Venture Exchange policies, Navion said it will request that trading in its common shares resume. The company expects trading to resume, but did not provide a date for that process.
Navion is a capital pool company established under TSX Venture Exchange policies. It has not started operations and holds no assets other than cash. Its principal business is identifying and evaluating assets or businesses for a potential Qualifying Transaction.
As of the date of the announcement, Navion had 4,600,000 common shares issued and outstanding, together with 460,000 options and 250,000 agent options. The options and agent options are exercisable before five years from the date of issuance at a price of $0.10 per common share.
Navion said statements concerning its future plans, including its proposed goal of completing a Qualifying Transaction, are forward-looking information. The company said those statements reflect its current views and intentions regarding future events and the information currently available to it, and are subject to risks, uncertainties and assumptions.
The risks identified by Navion include its ability to implement business strategies and pursue business opportunities, the state of the capital markets, the availability of funds and resources to pursue operations, and general economic, market and business conditions. The company said actual results or events may differ materially if these risks arise or if the assumptions underlying the forward-looking information prove incorrect.
Navion said the forward-looking information is made as of the date of the announcement and that it does not undertake to publicly update or revise it except as required by applicable law.
Navion Capital II Inc. announced that it had terminated its previously announced non-binding letter of intent with Maple Brain Healthcare Inc. The LOI concerned a proposed Qualifying Transaction under Policy 2.4 - Capital Pool Companies of the TSX Venture Exchange Corporate Finance Manual.
Navion Capital II Inc.'s letter of intent with Maple Brain Healthcare Inc. was dated October 24, 2025. The Company announced its termination on October 13, 2026.
The non-binding LOI was intended to support a proposed Qualifying Transaction between Navion Capital II Inc. and Maple Brain Healthcare Inc. The announcement does not provide further transaction terms.
Navion Capital II Inc. said it will continue to evaluate assets and businesses, including monitoring Maple Brain as it continues to develop its business, with a view to completing a Qualifying Transaction.
Navion Capital II Inc. said it will request a resumption of trading in its common shares in accordance with TSX Venture Exchange policies and expects resumption of trading. The announcement does not give a date for the expected resumption.
Navion Capital II Inc.'s shares trade on the TSX Venture Exchange under the ticker symbol TSXV:NVN.P.
Navion Capital II Inc. is a capital pool company created under the policies of the TSX Venture Exchange. Its principal business is identifying and evaluating assets or businesses with a view to completing a Qualifying Transaction.
Navion Capital II Inc. has not commenced operations and has no assets other than cash, according to the announcement.
As of October 13, 2026, Navion Capital II Inc. had 4,600,000 common shares issued and outstanding, along with 460,000 options and 250,000 agent options. The options and agent options are exercisable before five years from the date of issuance at a price of $0.10 per common share.
Navion Capital II Inc. identifies risks including its ability to implement business strategies and pursue business opportunities, the state of the capital markets, the availability of funds and resources to pursue operations, and general economic, market and business conditions. The Company says actual results or events may differ materially if risks or underlying assumptions prove incorrect, and it does not undertake to publicly update or revise the forward-looking information except as required by applicable law.